15 September 2023
15 September 2023
The vaccine is intended for active immunisation for the prevention of Covid-19 in those aged six months and above.
Alnylam’s Onpattro received a recommendation from an FDA advisory committee panel for a cardiomyopathy label expansion.
The move, which “addresses the high unmet need” for acute migraine treatment, is expected to help 13,000 patients on the NHS.
The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.
First Wave will repurpose Sanofi’s Alzheimer’s drug as a gastrointestinal therapy with plans to initiate clinical trials in 2024.
Frametact will make upfront and milestone payments totalling $60m to Cure Genetics.
RS will collaborate with Charles River and Valo Health in deploying Logica to discover significant new medicines.
The company’s programmes are in preclinical and clinical development across immunology, oncology and infectious disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
